This may have a negative effect on the efficacy of PD-1 or programmed death-ligand 1 (PD-L1) monoclonal antibodies (mAb) against several cancers, such as renal cell, non-small-cell lung, melanoma, and urothelial cancers3–6. Here, PDCD1 is linked to cancer.